ArticleBMC veterinary research2026
Development of an automated chemiluminescence immunoassay for detection of IgA antibodies against porcine epidemic diarrhea virus spike.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPorcine epidemic diarrhoea virus (PEDV) causes substantial financial losses on pig farming worldwide. Monitoring PEDV-specific IgA antibodies is essential for assessing vaccine efficacy. In this study, we developed a fully automated chemiluminescence immunoassay (CLIA) for the detection of PEDV IgA antibodies in both serum and milk.
resultsThis S1-CLIA utilizes recombinant S1 protein-coated magnetic particles (S1-MPs) for antibody capture and an acridinium ester-labeled mouse anti-pig IgA monoclonal antibody (mpIgA-AE) to generate chemiluminescence signals. Under optimized conditions, S1-CLIA achieved a diagnostic sensitivity of 96.30% and specificity of 98.48%, with a cut-off index of 1.0. S1-CLIA exhibited excellent repeatability (coefficient of variation < 10%) and no cross-reactivity with sera positive for other common swine pathogens. Compared to a commercial enzyme-linked immunosorbent assay (ELISA), S1-CLIA achieved 93.93% agreement rate, but offered a significantly broader dynamic range (35.48-fold). Notably, S1-CLIA results correlated well with virus neutralization titers (VNT), yielding R² values of 0.6660 (serum) and 0.7639 (milk).
conclusionsWith capability of fully automated testing, this novel S1-CLIA presents a robust platform for large-scale evaluation of PEDV immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.